FAV 201

Drug Profile

FAV 201

Alternative Names: FAV-201; T-cell lymphoma vaccine - Favrille; Torrex

Latest Information Update: 02 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Favrille
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cutaneous T cell lymphoma

Most Recent Events

  • 30 Nov 2011 FAV 201 is available for licensing as of 30 Nov 2011. http://www.mmrvideos.com/
  • 15 Jun 2010 MMR Information Systems is now called MMRGlobal
  • 31 Jan 2009 MMR Information Systems acquires Favrille
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top